trial

D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions

NCTId NCT01981759
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 58 (actual)
Sponsored by NYU Langone Health
Primary completion 2017-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
58 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-02
Primary completion
2017-05
Eligibility
ALL · 18 Years · 68 Years

Interventions & indications

Drugs
d-cycloserineCognitive Behavioral Therapy

Sponsors

NYU Langone HealthLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Donald C. Goff, MDPrincipal Investigator

Sites

2 total
Baltimore, United StatesNew York, United States

Facts & assertions

4 sourced
Enrollment
58
Phase
PHASE4
Primary Completion Date
2017-05
Status
COMPLETED
relationships
The graph out of here
drug
d-cycloserine
drug
Cognitive Behavioral Therapy
drug
lead_sponsor
NYU Langone Health
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizoaffective Disorder
indication
Schizophrenia, Paranoid
indication
Psychotic Disorders
indication
investigator
Donald C. Goff, MD
person